



[SOBRE NOSOTROS](#) ▾

[NUESTROS SERVICIOS](#) ▾

[AZIERTA BLOG](#)

[EMPLEO](#)

[CONTÁCTANOS](#) ▾

[FUNDACIÓN AZIERTA](#)

# Webinar

## Elemental Impurities (ICH Q3D): Training & Case Studies

[Home](#) / [Elemental Impurities \(ICH Q3D\): Training & Case Studies](#)

# October 19<sup>th</sup> 2017 (Thursday); Starting at 15:00 CEST (Spain)

*Duration: 60 minutes (The attendance is free, online and previous  
registration in the form of the bottom)*



**Paulino Alonso**

(Toxicology Technician & ICH Q3D Responsible at Azierta)



**Pablo Cobo**

(Biopharma Testing Manager at Kymos Pharma Services)

## Summary of the content

- The implementation of the ICH Q3D requirements is already ongoing for finished drug products. In this Webinar, we will highlight the key-points of the normative: scientific risk assessments and methods for analytical testing. The different implementation approaches (component approach and product approach) will be reviewed and analyzed and the webinar will conclude with a case study.

---

- We intend to cover all possible questions coming from a broad audience using the expertise of Azierta with scientific risk assessments, and the specialist knowledge of Kymos with analytical testing.

## Webinar modules

- 1 Background of ICH Q3D
- 2 Introduction, objective, important dates
- 3 Key aspects for the implementation
- 4 How to do a risk assessment; component approach vs product approach
- 5 Analytical testing: Techniques and methodologies suitable for EI analysis
- 6 Analytical testing: Development and validation of analytical methods
- 7 Analytical testing: Project strategies
- 8 Case study: a real example
- 9 Questions

# Join us

Name

Last name

Email

Country

Company

I have read and I agree to the private policy

*The party responsible for processing your data is AZIERTA CONTRACT SCIENTIFIC SUPPORT CONSULTING, S.L. (hereinafter, AZIERTA). At AZIERTA we process your data for the purpose of promoting our products and services. We will create profiles to adapt the information sent according to your interests. The legitimacy for the processing of your data is based on the consent requested from you. No data will be transferred to third parties, except under legal obligation. You can access, rectify and delete the data as well as exercise other rights, as explained in the additional information. You can consult the additional information on Data Protection on our website: [Private Policy](#)*

Send

- More than 600 reports already delivered
- Database with more than 1000 excipients and APIs
- Reports reviewed by Health Authorities



## *EUROTOX Corporate Members*

## EUROPEAN PARTNERS



### **Maas & Peither AG**

Schopfheim (Deutschland)

+49 7622 666 86-70

[www.gmp-verlag.de](http://www.gmp-verlag.de)



### **KYMOS PHARMA SERVICES**

Barcelona (Spain)

+34 935 481 848

[www.kymos.com](http://www.kymos.com)



## Azierta en

**Madrid** 

Vía de las Dos  
Castillas 33,  
Edificio 7

28224 Pozuelo de  
Alarcón (Madrid)

91 277 10 76

info@azierta.eu

**Barcelona** 

**Bogotá** 

**Lima** 

## Últimas entradas del blog

¿Te has dado de alta ya en la nueva base de datos de evdas para detección de señales?

13 septiembre, 2017

Revisión de expedientes técnicos por el Organismo Notificado Español

12 septiembre, 2017

La seguridad en la participación de un ensayo clínico

30 agosto, 2017

Etapas de evaluación de la exposición ocupacional a una sustancia Química/API.

21 agosto, 2017

## Cookies y Aviso Legal

[Aviso legal](#)

[Política de Cookies](#)

[Política de Privacidad](#)